Literature DB >> 22855650

Neuropsychopathology in 7 Patients with the 22q13 Deletion Syndrome: Presence of Bipolar Disorder and Progressive Loss of Skills.

A Denayer1, H Van Esch, T de Ravel, J-P Frijns, G Van Buggenhout, A Vogels, K Devriendt, J Geutjens, P Thiry, A Swillen.   

Abstract

The 22q13 deletion syndrome is characterised by intellectual disability (ID), delayed or absent speech, autistic-like behaviour and minor, nonspecific dysmorphic features. The deletion of the SHANK3 gene is thought to be responsible for these features. In this study, the clinical data of 7 patients with the 22q13 deletion syndrome are presented, obtained by clinical genetic examination, direct behavioural observation and by interview of family members and/or caregivers, complemented by behavioural questionnaires. The specific focus was on behaviour, psychopathology and the level of functioning during life course in order to determine common features that might contribute to the delineation of the syndrome. Major findings were a high incidence of psychiatric disorders, more in particular bipolar disorder (BPD) and attention deficit hyperactivity disorder (ADHD), and a sudden deterioration after acute events, in addition to a progressive loss of skills over years. Therefore, a deletion of SHANK3 may result in a dysfunctional nervous system, more susceptible to developmental problems and psychiatric disorders on the one hand, less able to recuperate after psychiatric and somatic events, and more vulnerable to degeneration at long term on the other hand. These results are exploratory and need to be confirmed in a larger sample.

Entities:  

Year:  2012        PMID: 22855650      PMCID: PMC3398818          DOI: 10.1159/000339119

Source DB:  PubMed          Journal:  Mol Syndromol        ISSN: 1661-8769


  15 in total

Review 1.  Ring chromosome 22 and mood disorders.

Authors:  R Sovner; A Stone; C Fox
Journal:  J Intellect Disabil Res       Date:  1996-02

Review 2.  Toward an evidence-based assessment of pediatric bipolar disorder.

Authors:  Eric A Youngstrom; Robert L Findling; Jen Kogos Youngstrom; Joseph R Calabrese
Journal:  J Clin Child Adolesc Psychol       Date:  2005-09

3.  MLC1 gene is associated with schizophrenia and bipolar disorder in Southern India.

Authors:  Ranjana Verma; Mitali Mukerji; Deepak Grover; Chandrika B-Rao; Swapan Kumar Das; Shobana Kubendran; Sanjeev Jain; Samir K Brahmachari
Journal:  Biol Psychiatry       Date:  2005-07-01       Impact factor: 13.382

4.  The PDD-MRS: an instrument for identification of autism spectrum disorders in persons with mental retardation.

Authors:  Dirk Kraijer; Annelies de Bildt
Journal:  J Autism Dev Disord       Date:  2005-08

5.  22q13 deletion syndrome.

Authors:  M C Phelan; R C Rogers; R A Saul; G A Stapleton; K Sweet; H McDermid; S R Shaw; J Claytor; J Willis; D P Kelly
Journal:  Am J Med Genet       Date:  2001-06-15

Review 6.  22q13.3 deletion syndrome: a recognizable malformation syndrome associated with marked speech and language delay.

Authors:  Kristina Cusmano-Ozog; Melanie A Manning; H Eugene Hoyme
Journal:  Am J Med Genet C Semin Med Genet       Date:  2007-11-15       Impact factor: 3.908

7.  Emerging patterns of cryptic chromosomal imbalance in patients with idiopathic mental retardation and multiple congenital anomalies: a new series of 140 patients and review of published reports.

Authors:  B Menten; N Maas; B Thienpont; K Buysse; J Vandesompele; C Melotte; T de Ravel; S Van Vooren; I Balikova; L Backx; S Janssens; A De Paepe; B De Moor; Y Moreau; P Marynen; J-P Fryns; G Mortier; K Devriendt; F Speleman; J R Vermeesch
Journal:  J Med Genet       Date:  2006-02-20       Impact factor: 6.318

8.  Terminal 22q deletion syndrome: a newly recognized cause of speech and language disability in the autism spectrum.

Authors:  Melanie A Manning; Suzanne B Cassidy; Carol Clericuzio; Athena M Cherry; Stuart Schwartz; Louanne Hudgins; Gregory M Enns; H Eugene Hoyme
Journal:  Pediatrics       Date:  2004-08       Impact factor: 7.124

Review 9.  22q13 deletion syndrome: an update and review for the primary pediatrician.

Authors:  Joaquim M Havens; Jeannie Visootsak; Mary C Phelan; John M Graham
Journal:  Clin Pediatr (Phila)       Date:  2004 Jan-Feb       Impact factor: 1.168

10.  Molecular mechanisms generating and stabilizing terminal 22q13 deletions in 44 subjects with Phelan/McDermid syndrome.

Authors:  Maria Clara Bonaglia; Roberto Giorda; Silvana Beri; Cristina De Agostini; Francesca Novara; Marco Fichera; Lucia Grillo; Ornella Galesi; Annalisa Vetro; Roberto Ciccone; Maria Teresa Bonati; Sabrina Giglio; Renzo Guerrini; Sara Osimani; Susan Marelli; Claudio Zucca; Rita Grasso; Renato Borgatti; Elisa Mani; Cristina Motta; Massimo Molteni; Corrado Romano; Donatella Greco; Santina Reitano; Anna Baroncini; Elisabetta Lapi; Antonella Cecconi; Giulia Arrigo; Maria Grazia Patricelli; Chiara Pantaleoni; Stefano D'Arrigo; Daria Riva; Francesca Sciacca; Bernardo Dalla Bernardina; Leonardo Zoccante; Francesca Darra; Cristiano Termine; Emanuela Maserati; Stefania Bigoni; Emanuela Priolo; Armand Bottani; Stefania Gimelli; Frederique Bena; Alfredo Brusco; Eleonora di Gregorio; Irene Bagnasco; Ursula Giussani; Lucio Nitsch; Pierluigi Politi; Maria Luisa Martinez-Frias; Maria Luisa Martínez-Fernández; Nieves Martínez Guardia; Anna Bremer; Britt-Marie Anderlid; Orsetta Zuffardi
Journal:  PLoS Genet       Date:  2011-07-14       Impact factor: 5.917

View more
  40 in total

1.  SHANK Mutations May Disorder Brain Development.

Authors:  Martin Poot
Journal:  Mol Syndromol       Date:  2015-02

2.  Deep Phenotyping of Development, Communication and Behaviour in Phelan-McDermid Syndrome.

Authors:  Gilles Droogmans; Ann Swillen; Griet Van Buggenhout
Journal:  Mol Syndromol       Date:  2019-11-05

Review 3.  Subacute Neuropsychiatric Syndrome in Girls With SHANK3 Mutations Responds to Immunomodulation.

Authors:  Alexandra L Bey; Mark P Gorman; William Gallentine; Teresa M Kohlenberg; Jennifer Frankovich; Yong-Hui Jiang; Keith Van Haren
Journal:  Pediatrics       Date:  2020-02       Impact factor: 7.124

Review 4.  Neurobiology of autism gene products: towards pathogenesis and drug targets.

Authors:  Kristel T E Kleijer; Michael J Schmeisser; Dilja D Krueger; Tobias M Boeckers; Peter Scheiffele; Thomas Bourgeron; Nils Brose; J Peter H Burbach
Journal:  Psychopharmacology (Berl)       Date:  2014-01-14       Impact factor: 4.530

Review 5.  Loss of skills and onset patterns in neurodevelopmental disorders: Understanding the neurobiological mechanisms.

Authors:  Audrey Thurm; Elizabeth M Powell; Jeffrey L Neul; Ann Wagner; Lonnie Zwaigenbaum
Journal:  Autism Res       Date:  2017-12-11       Impact factor: 5.216

Review 6.  Phelan-McDermid Syndrome and SHANK3: Implications for Treatment.

Authors:  Jesse L Costales; Alexander Kolevzon
Journal:  Neurotherapeutics       Date:  2015-07       Impact factor: 7.620

Review 7.  Phelan McDermid Syndrome: From Genetic Discoveries to Animal Models and Treatment.

Authors:  Hala Harony-Nicolas; Silvia De Rubeis; Alexander Kolevzon; Joseph D Buxbaum
Journal:  J Child Neurol       Date:  2015-09-08       Impact factor: 1.987

8.  Clinical and genomic evaluation of 201 patients with Phelan-McDermid syndrome.

Authors:  Sara M Sarasua; Luigi Boccuto; Julia L Sharp; Alka Dwivedi; Chin-Fu Chen; Jonathan D Rollins; R Curtis Rogers; Katy Phelan; Barbara R DuPont
Journal:  Hum Genet       Date:  2014-01-31       Impact factor: 4.132

9.  Deficiency of Shank2 causes mania-like behavior that responds to mood stabilizers.

Authors:  Andrea L Pappas; Alexandra L Bey; Xiaoming Wang; Mark Rossi; Yong Ho Kim; Haidun Yan; Fiona Porkka; Lara J Duffney; Samantha M Phillips; Xinyu Cao; Jin-Dong Ding; Ramona M Rodriguiz; Henry H Yin; Richard J Weinberg; Ru-Rong Ji; William C Wetsel; Yong-Hui Jiang
Journal:  JCI Insight       Date:  2017-10-19

Review 10.  Modeling autism by SHANK gene mutations in mice.

Authors:  Yong-Hui Jiang; Michael D Ehlers
Journal:  Neuron       Date:  2013-04-10       Impact factor: 17.173

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.